Asarina Pharma

1 investor følger denne virksomhed

ViserAlle indholdstyper

Selskabsmeddelelse16.9.2024, 18.00

Asarina Pharma AB (publ) shares to be delisted and the last day of trading is 1 October 2024

Selskabsmeddelelse13.9.2024, 09.00

Asarina Pharma applies for the delisting of the company's shares

Selskabsmeddelelse21.8.2024, 09.30

Bulletin from the extraordinary general meeting and first control meeting in Asarina Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Selskabsmeddelelse22.7.2024, 06.00

NOTICE OF EXTRAORDINARY GENERAL MEETING AND FIRST CONTROL MEETING IN ASARINA PHARMA AB (PUBL)

Selskabsmeddelelse18.7.2024, 15.45

ASARINA PHARMA ANNOUNCES OUTCOME OF PARTNERING PROCESS, CONTROL BALANCE SHEET AND PROPOSAL TO LIQUIDATE

Selskabsmeddelelse27.6.2024, 09.33

Bulletin from the Annual General Meeting of Asarina Pharma AB (publ)

Selskabsmeddelelse4.6.2024, 20.54

ASARINA PHARMA AB (PUBL) RELEASES ANNUAL REPORT 2023

Selskabsmeddelelse28.5.2024, 20.00

Asarina Pharma AB announces new date for the release of Annual Report for 2023

Selskabsmeddelelse21.5.2024, 09.50

Asarina Pharma AB announces new date for the release of Annual Report for 2023

Selskabsmeddelelse27.2.2024, 07.30

ASARINA PHARMA AB (PUBL) RELEASES YEAR-END REPORT 2023

Selskabsmeddelelse30.11.2023, 09.30

Asarina Pharma AB changes Certified Adviser to Carnegie Investment Bank AB

Selskabsmeddelelse16.11.2023, 07.33

Asarina Pharma updates on partnering and financials

Selskabsmeddelelse23.8.2023, 06.30

Asarina Pharma AB (publ) releases First Half-Year Report (H1/2023)

Selskabsmeddelelse23.5.2023, 07.02

Positive Tourette Syndrome results to be presented at ESSTS, 15th European Conference on Tourette Syndrome and Tic Disorders

Selskabsmeddelelse22.5.2023, 09.15

Bulletin from the Annual General Meeting of Asarina Pharma AB (publ)

Selskabsmeddelelse5.5.2023, 11.33

Asarina Pharma's positive Phase IIa Tourette Syndrome results to be presented at TicCon, the Virtual National Conference of the Tourette Association of America

Selskabsmeddelelse28.4.2023, 18.30

Asarina Pharma AB (publ) releases Annual Report 2022

Selskabsmeddelelse18.4.2023, 08.39

Asarina Pharma: NOTICE OF ANNUAL GENERAL MEETING IN ASARINA PHARMA AB (PUBL)

Selskabsmeddelelse1.4.2023, 12.20

Asarina Pharma publishes positive results from its Phase IIa study of Sepranolone in Tourette Syndrome

Selskabsmeddelelse27.2.2023, 07.30

Asarina Pharma AB (publ) releases Year-End Report 2022

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.